FDA warns Singapore OTC drug maker TSP Solutions over missing release testing and component identity checks for sunscreens.
What happened
FDA found the violations during a review of records TSP Solutions submitted after FDA's September 9, 2025, request for records. The records did not show adequate finished-product testing for sunscreen active ingredient content, impurities, or microorganisms, and they showed reliance on supplier certificates of analysis without identity testing of incoming components. FDA also found the quality unit did not adequately oversee production, laboratory controls, or stability.
What FDA found
TSP Solutions did not test each batch of sunscreen for active ingredient identity and strength, impurities, or harmful microorganisms before release.
21 CFR 211.165(a) and 211.165(b)TSP Solutions did not perform at least one identity test on each incoming component and relied on supplier certificates of analysis without validating the supplier's test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)TSP Solutions' quality unit did not ensure adequate production controls, laboratory controls, or an ongoing stability program.
21 CFR 211.22; 211.100(a); 211.160(b); 211.166(a)
What FDA wants
FDA asks TSP Solutions to respond in writing within 15 business days of receipt, identifying FEI 3023093622 and ATTN: Bryce Hammer, and to address the CGMP violations with full testing plans, retain-sample results, and a review of its material system. FDA also recommends a qualified CGMP consultant and may withhold approvals or continue refusing imports until compliance is confirmed.
Who should pay attention
- brands that use TSP Solutions as a contract manufacturer for OTC drugs or sunscreens
- U.S. distributors and retailers selling imported OTC drug products
- suppliers and buyers relying on TSP Solutions' certificates of analysis
This is a summary. Read the original letter on fda.gov.